Inventor · disambiguated record
Peter Peizhi Luo
Also filed as: LUO PETER · LUO PETER PEIZHI
19 granted patents·21 pending applications·293 citations·filing 2002–2024
94Inventor score
Top patents by PatentIndex Score
40 records- 0195US8188233B21B20 PCSK9 antagonistsCONDRA JON H·Filed 2009·Granted May 29, 2012·91 cites·22 claims
- 0295US8188234B21D05 PCSK9 antagonistsCONDRA JON H·Filed 2009·Granted May 29, 2012·98 cites·19 claims
- 0392US11242395B2Anti-CD137 molecules and use thereofADAGENE INC·Filed 2018·Granted Feb 8, 2022·13 cites·29 claims
- 0488US11359016B2Anti-CTLA4 antibodies and methods of making and using the sameADAGENE INC·Filed 2019·Granted Jun 14, 2022·5 cites·40 claims
- 0587US6605535B1Method of filling trenches using vapor-liquid-solid mechanismPROMOS TECHNOLOGIES INC·Filed 2002·Granted Aug 12, 2003·53 cites·20 claims
- 0686US11859003B2Method for treating cancer using anti-CD137 antibodyADAGENE INC·Filed 2018·Granted Jan 2, 2024·3 cites·18 claims
- 0784US7462698B2Anti-CD26 antibodies and methods of use thereofY S THERAPEUTICS CO LTD·Filed 2006·Granted Dec 9, 2008·11 cites·33 claims
- 0881US11952681B2Masked activatable CD137 antibodiesADAGENE INC·Filed 2019·Granted Apr 9, 2024·1 cites·43 claims
- 0981US8030469B2Anti-CD26 antibodies and methods of use thereofSBI INCUBATION CO LTD·Filed 2008·Granted Oct 4, 2011·4 cites·2 claims
- 1080US11585014B2Dynamic human antibody light chain librariesADAGENE INC·Filed 2017·Granted Feb 21, 2023·2 cites·23 claims
- 1178US8802827B2AX1 PCSK9 antagonistsLUO PETER PEIZHI·Filed 2010·Granted Aug 12, 2014·6 cites·9 claims
- 1275US11578426B2Dynamic human heavy chain antibody librariesADAGENE INC·Filed 2017·Granted Feb 14, 2023·1 cites·34 claims
- 1375US2024141046A1Anti-ctla4 antibodies and methods of making and using the sameADAGENE INC·Filed 2023·Application pending·0 cites
- 1474US12503693B2Integrated system for library construction, affinity binder screening and expression thereofADAGENE INC·Filed 2021·Granted Dec 23, 2025·0 cites·6 claims
- 1573US2024150749A1Activatable antibodies and methods of making and using thereofADAGENE INC·Filed 2023·Application pending·0 cites
- 1671US12378319B2Anti-CD137 molecules and use thereofADAGENE INC·Filed 2021·Granted Aug 5, 2025·0 cites·13 claims
- 1770US12385162B2Dynamic human heavy chain antibody librariesADAGENE INC·Filed 2023·Granted Aug 12, 2025·0 cites·32 claims
- 1870US8877900B2AX132 PCSK9 antagonistsLUO PETER PEIZHI·Filed 2010·Granted Nov 4, 2014·4 cites·9 claims
- 1969US2023287597A1Dynamic human antibody light chain librariesADAGENE INC·Filed 2023·Application pending·0 cites
- 2066US2019241886A1Precision/context-dependent activatable antibodies, and methods of making and using the sameADAGENE INC·Filed 2019·Application pending·0 cites
- 2165US8637435B2Eukaryotic cell display systemsWANG KEVIN CAILI·Filed 2008·Granted Jan 28, 2014·1 cites·6 claims
- 2265US2024279350A1CD40-Binding ProteinsSANOFI SA·Filed 2024·Application pending·0 cites
- 2364US11692036B2Anti-CTLA4 antibodies and methods of making and using the sameADAGENE INC·Filed 2019·Granted Jul 4, 2023·0 cites·28 claims
- 2462US2024262923A1Anti-pd-1×4-1bb binding proteinsGENZYME CORP·Filed 2023·Application pending·0 cites
- 2561US2025257133A1Anti-CD28 Antibodies and Methods of Use ThereofADAGENE PTE LTD·Filed 2023·Application pending·0 cites
- 2661US2025188179A1Anti-cd137 antibodies and methods of making and using the sameADAGENE PTE LTD·Filed 2023·Application pending·0 cites
- 2759US2025326847A1Activatable anti-ctla4 antibodies for treating cancerADAGENE PTE LTD·Filed 2023·Application pending·0 cites
- 2857US2024417463A1Anti-cd47 antibodies and methods of use thereofADAGENE PTE LTD·Filed 2022·Application pending·0 cites
- 2956US2024209092A1Combination therapies for treating cancerADAGENE INC·Filed 2022·Application pending·0 cites
- 3056US2016145604A1An Integrated System for Library Construction, Affinity Binder Screening and Expression ThereofADAGENE INC·Filed 2013·Application pending·0 cites
- 3156US2025326860A1Anti-cd3 antibodies and methods of use thereofADAGENE PTE LTD·Filed 2022·Application pending·0 cites
- 3254US2024209091A1Methods for treating cancer using anti-ctla4 antibodiesADAGENE PTE LTD·Filed 2022·Application pending·0 cites
- 3352US2023242663A1Combination therapy comprising anti-cd137 antibodiesADAGENE PTE LTD·Filed 2021·Application pending·0 cites
- 3451US2023133118A1Compositions and methods for treating cancerADAGENE AG·Filed 2021·Application pending·0 cites
- 3549US2012329679A1Eukaryotic cell display systemsWANG KEVIN CAILI·Filed 2012·Application pending·0 cites
- 3648US11485977B2Methods and systems for autoinduction of protein expressionADAGENE INC·Filed 2014·Granted Nov 1, 2022·0 cites·14 claims
- 3747US2022089757A1Anti-cd137l antibodies and methods of using sameADAGENE PTE LTD·Filed 2020·Application pending·0 cites
- 3845US2020377608A1Methods for using cd137 ligand as a biomarker for treatment with anti-cd137 antibodyLUO PETER PEIZHI·Filed 2018·Application pending·0 cites
- 3945US2023124669A1Heterodimeric proteins with fc mutationsADAGENE AG·Filed 2021·Application pending·0 cites
- 4042US2009082221A1Cross-Species and Multi-Species Display SystemsWANG KEVIN CAILI·Filed 2007·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Peter Peizhi Luo files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →